Inspiration of the WHO Updated on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication

doi:10.3969/j.issn.1000-6621.2021.08.002

Abstract

Abstract:

Rapid and accurate diagnosis of tuberculosis and drug-resistant tuberculosis is essential to tuberculosis prevention and control. The World Health Organization issued the Update on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication in February 18th 2021. This inspiration provided an interpretation of detailed introduction of the technologies and their technical performance, and elaborated the experience, potential effects on the current national tuberculosis control program and implementation considerations of these technologies.

Key words: Mycobacterium tuberculosis, Nucleic acid amplification techniques, Drug resistance,bacterial

XIA Hui, ZHAO Yan-lin. Inspiration of the WHO Updated on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication[J]. Chinese Journal of Antituberculosis, 2021, 43(8): 761-765. doi: 10.3969/j.issn.1000-6621.2021.08.002

Figures/Tables 1

References 11

[1]	World Health Organization. Update on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication. Geneva: World Health Organization, 2021.
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection. Geneva: World Health Organization, 2020.
[3]	World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization, 2021.
[4]	de Vos M, Scott L, David A, et al. Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. J Clin Microbiol, 2021, 59(3):02168-20. doi: 10.1128/JCM.02168-20.
[5]	Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J, 2008, 31(4):904-905. doi: 10.1183/09031936.00159807. doi: 10.1183/09031936.00159807 URL
[6]	Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis:a multicentre,open-label,partially randomised,phase 2b trial. Lancet Respir Med, 2019, 7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. doi: 10.1016/S2213-2600(19)30366-2 URL
[7]	World Health Organization. WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment. Geneva: World Health Organization, 2010.
[8]	Bainomugisa A, Gilpin C, Coulter C, et al. New Xpert MTB/XDR: added value and future in the field. Eur Respir J, 2020, 56(5):2003616. doi: 10.1183/13993003.03616-2020. doi: 10.1183/13993003.03616-2020 URL
[9]	Cao Y, Parmar H, Gaur RL, et al. Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid-,Fluoroquinolone,and Second-Line-Injectable Drug-Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. J Clin Microbiol, 2021, 59(3):02314-20. doi: 10.1128/JCM.02314-20.
[10]	Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med, 2017, 377(11):1043-1054. doi: 10.1056/NEJMoa1614915. doi: 10.1056/NEJMoa1614915 URL
[11]	Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of drug-resistant tuberculosis by xpert MTB/RIF in Swaziland. N Engl J Med, 2015, 372(12):1181-1182. doi: 10.1056/NEJMc1413930. doi: 10.1056/NEJMc1413930 URL

项目	罗氏	碧迪	海恩生命科学	雅培
最大样本处理量/批次	94	24	94	94
灭活步骤	2:1 MIS^a,涡旋30~60s	2:1 Max STR^a,振荡10次,孵育5min,振荡10次	2:1液化,涡旋	3:1 IR^a,颠倒几次,涡旋20~30s
灭活孵育时间	1h	25min	30min	1h,在20min时涡旋振荡20~30s
是否需要超声	每份标本超声1min, 离心60s	否	否	否
DNA提取、扩增及检测	2h 30min报告结果	3h 41min报告结果	提取DNA 2h,封板后转移至扩增仪, 1h 41min后报告结果	提取DNA 4h 22min, 封板转移至扩增仪,2h 30min后报告结果
MTBC检测靶标	16S rRNA,esxJ,esxK,esxM,esxP,esxW	IS6110,IS1081,devR	rpoB	Pab,IS6110

[1]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[2]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[3]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[4]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[5]	Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373.
[6]	Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163.
[7]	Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111.
[8]	Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60.
[9]	Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76.
[10]	Mei Chunlin, Yang Chengqing, Du Ronghui, Cao Tanze, Feng Wei, Chen Shufang, Liu Xiuping, Ou Jiali. Diagnostic accuracy of GeneXpert MTB/RIF in detecting pulmonary tuberculosis with extremely low loads of MTB in bronchoalveolar lavage fluid in general hospitals [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1037-1041.
[11]	Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068.
[12]	Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang. Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082.
[13]	Xu Chunhua, Zhu Shiyu, Hu Yi, Yi Kehua, Song Canlei, Wang Zichun, Wu Yong, Wang Qing, Yang Qianru, Shen Xin. Analysis of screening effect of recombinant Mycobacterium tuberculosis fusion protein in screening Mycobacterium tuberculosis infection in close contacts of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 897-902.
[14]	Zhang Lanyue, Wang Yingchao, Liu Weiyi, Shang Xuetian, Jia Hongyan, Zhu Chuanzhi, Zhang Zongde, Pan Liping. Study on the effect of thiol acetyltransferase mshD on the growth and stress response of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 935-941.
[15]	Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950.